Filing Details

Accession Number:
0001209191-14-004013
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-21 16:01:26
Reporting Period:
2014-01-16
Filing Date:
2014-01-21
Accepted Time:
2014-01-21 16:01:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1338042 Aegerion Pharmaceuticals Inc. AEGR Pharmaceutical Preparations (2834) 202960116
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1527134 Mark Sumeray C/O Aegerion Pharmaceuticals, Inc.
101 Main Street, Suite 1850
Cambridge MA 02142
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-01-16 2,000 $13.01 2,000 No 4 M Direct
Common Stock Disposition 2014-01-16 1,900 $58.59 100 No 4 S Direct
Common Stock Disposition 2014-01-16 100 $59.51 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-01-16 2,000 $0.00 2,000 $13.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
117,000 2021-11-01 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $58.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. 100,000 shares of common stock underlying this option vest over a 46-month period, with one-twenty-fourth of the shares vesting on the grant date of November 1, 2011 and the remainder of the shares vesting monthly thereafter in forty-six equal installments; 30,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Juxtapid by the U.S. Food and Drug Administration; 20,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Lojuxta by the European Medicines Agency; and 10,000 shares of common stock underlying this option vest monthly in equal installments over a four-year period commencing upon approval of Juxtapid for the treatment of pediatric patients.